|
1
|
Henley SJ, Larson TC, Wu M, Antao VC,
Lewis M, Pinheiro GA and Eheman C: Mesothelioma incidence in 50
states and the District of Columbia, United States, 2003-2008. Int
J Occup Environ Health. 19:1–10. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Scherpereel A: Malignant pleural
mesothelioma: new treatments, new hopes? Eur Respir J.
49:17003192017. View Article : Google Scholar
|
|
3
|
Goudar RK: Review of pemetrexed in
combination with cisplatin for the treatment of malignant pleural
mesothelioma. Ther Clin Risk Manag. 4:205–211. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Toyooka S, Kishimoto T and Date H:
Advances in the molecular biology of malignant mesothelioma. Acta
Med Okayama. 62:1–7. 2008.PubMed/NCBI
|
|
5
|
Russo M, Siravegna G, Blaszkowsky LS,
Corti G, Crisafulli G, Ahronian LG, Mussolin B, Kwak EL, Buscarino
M, Lazzari L, et al: Tumor heterogeneity and lesion-specific
response to targeted therapy in colorectal cancer. Cancer Discov.
6:147–153. 2016. View Article : Google Scholar :
|
|
6
|
Murtaza M, Dawson SJ, Pogrebniak K, Rueda
OM, Provenzano E, Grant J, Chin SF, Tsui DW, Marass F, Gale D, et
al: Multifocal clonal evolution characterized using circulating
tumour DNA in a case of metastatic breast cancer. Nat Commun.
6:87602015. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Alix-Panabières C, Schwarzenbach H and
Pantel K: Circulating tumor cells and circulating tumor DNA. Annu
Rev Med. 63:199–215. 2012. View Article : Google Scholar
|
|
8
|
Loginov VI, Pronina IV, Burdennyy AM,
Filippova EA, Kazubskaya TP, Kushlinsky DN, Utkin DO, Khodyrev DS,
Kushlinskii NE, Dmitriev AA, et al: Novel miRNA genes deregulated
by aberrant methylation in ovarian carcinoma are involved in
metastasis. Gene. 662:28–36. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Tian Y, Wei W, Li L and Yang R:
Down-regulation of miR-148a promotes metastasis by DNA methylation
and is associated with prognosis of skin cancer by targeting TGIF2.
Med Sci Monit. 21:3798–3805. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Croce CM: Causes and consequences of
microRNA dysregulation in cancer. Nat Rev Genet. 10:704–714. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Toyota M, Suzuki H, Sasaki Y, Maruyama R,
Imai K, Shinomura Y and Tokino T: Epigenetic silencing of
microRNA-34b/c and B-cell translocation gene 4 is associated with
CpG island meth-ylation in colorectal cancer. Cancer Res.
68:4123–4132. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Kubo T, Toyooka S, Tsukuda K, Sakaguchi M,
Fukazawa T, Soh J, Asano H, Ueno T, Muraoka T, Yamamoto H, et al:
Epigenetic silencing of microRNA-34b/c plays an important role in
the pathogenesis of malignant pleural mesothelioma. Clin Cancer
Res. 17:4965–4974. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
He L, He X, Lim LP, de Stanchina E, Xuan
Z, Liang Y, Xue W, Zender L, Magnus J, Ridzon D, et al: A microRNA
component of the p53 tumour suppressor network. Nature.
447:1130–1134. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Corney DC, Flesken-Nikitin A, Godwin AK,
Wang W and Nikitin AY: MicroRNA-34b and microRNA-34c are targets of
p53 and cooperate in control of cell proliferation and
adhesion-independent growth. Cancer Res. 67:8433–8438. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Suzuki R, Yamamoto E, Nojima M, Maruyama
R, Yamano HO, Yoshikawa K, Kimura T, Harada T, Ashida M, Niinuma T,
et al: Aberrant methylation of microRNA-34b/c is a predictive
marker of metachronous gastric cancer risk. J Gastroenterol.
49:1135–1144. 2014. View Article : Google Scholar :
|
|
16
|
Wu XD, Song YC, Cao PL, Zhang H, Guo Q,
Yan R, Diao DM, Cheng Y and Dang CX: Detection of miR-34a and
miR-34b/c in stool sample as potential screening biomarkers for
noninvasive diagnosis of colorectal cancer. Med Oncol. 31:8942014.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Muraoka T, Soh J, Toyooka S, Aoe K,
Fujimoto N, Hashida S, Maki Y, Tanaka N, Shien K, Furukawa M, et
al: The degree of microRNA-34b/c methylation in serum-circulating
DNA is associated with malignant pleural mesothelioma. Lung Cancer.
82:485–490. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Oxnard GR, Paweletz CP, Kuang Y, Mach SL,
O’Connell A, Messineo MM, Luke JJ, Butaney M, Kirschmeier P,
Jackman DM, et al: Noninvasive detection of response and resistance
in EGFR-mutant lung cancer using quantitative next-generation
genotyping of cell-free plasma DNA. Clin Cancer Res. 20:1698–1705.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Hindson BJ, Ness KD, Masquelier DA,
Belgrader P, Heredia NJ, Makarewicz AJ, Bright IJ, Lucero MY,
Hiddessen AL, Legler TC, et al: High-throughput droplet digital PCR
system for absolute quantitation of DNA copy number. Anal Chem.
83:8604–8610. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Sanmamed MF, Fernández-Landázuri S,
Rodríguez C, Zárate R, Lozano MD, Zubiri L, Perez-Gracia JL,
Martín-Algarra S and González A: Quantitative cell-free circulating
BRAFV600E mutation analysis by use of droplet digital PCR in the
follow-up of patients with melanoma being treated with BRAF
inhibitors. Clin Chem. 61:297–304. 2015. View Article : Google Scholar
|
|
21
|
Siravegna G, Marsoni S, Siena S and
Bardelli A: Integrating liquid biopsies into the management of
cancer. Nat Rev Clin Oncol. 14:531–548. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Soh J, Okumura N, Lockwood WW, Yamamoto H,
Shigematsu H, Zhang W, Chari R, Shames DS, Tang X, MacAulay C, et
al: Oncogene mutations, copy number gains and mutant allele
specific imbalance (MASI) frequently occur together in tumor cells.
PLoS One. 4:e74642009. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Suzawa K, Yamamoto H, Ohashi K, Hashida S,
Tomida S, Kubo T, Maki Y, Soh J, Tsukuda K, Kiura K, et al: Optimal
method for quantitative detection of plasma EGFR T790M mutation
using droplet digital PCR system. Oncol Rep. 37:3100–3106. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Jezkova E, Kajo K, Zubor P, Grendar M,
Malicherova B, Mendelova A, Dokus K, Lasabova Z, Plank L and Danko
J: Methylation in promoter regions of PITX2 and RASSF1A genes in
association with clinicopathological features in breast cancer
patients. Tumour Biol. 37:15707–15718. 2016. View Article : Google Scholar
|
|
25
|
Guo Y, Peng Y, Gao D, Zhang M, Yang W,
Linghu E, Herman JG, Fuks F, Dong G and Guo M: Silencing HOXD10 by
promoter region hypermethylation activates ERK signaling in
hepato-cellular carcinoma. Clin Epigenetics. 9:1162017. View Article : Google Scholar
|
|
26
|
Flanagan JM, Wilson A, Koo C, Masrour N,
Gallon J, Loomis E, Flower K, Wilhelm-Benartzi C, Hergovich A,
Cunnea P, et al: Platinum-based chemotherapy induces methylation
changes in blood DNA associated with overall survival in patients
with ovarian cancer. Clin Cancer Res. 23:2213–2222. 2017.
View Article : Google Scholar
|
|
27
|
Sun X, Yuan W, Hao F and Zhuang W:
Promoter methylation of RASSF1A indicates prognosis for patients
with stage II and III colorectal cancer treated with
oxaliplatin-based chemotherapy. Med Sci Monit. 23:5389–5395. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Cristaudo A, Bonotti A, Guglielmi G,
Fallahi P and Foddis R: Serum mesothelin and other biomarkers: What
have we learned in the last decade? J Thorac Dis. 10(Suppl 2):
S353–S359. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Bruno R, Alì G and Fontanini G: Molecular
markers and new diagnostic methods to differentiate malignant from
benign meso-thelial pleural proliferations: A literature review. J
Thorac Dis. 10(Suppl 2): S342–S352. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Hu ZD, Liu XF, Liu XC, Ding CM and Hu CJ:
Diagnostic accuracy of osteopontin for malignant pleural
mesothelioma: A systematic review and meta-analysis. Clin Chimica
Acta. 433:44–48. 2014. View Article : Google Scholar
|
|
31
|
Creaney J, Dick IM, Meniawy TM, Leong SL,
Leon JS, Demelker Y, Segal A, Musk AW, Lee YC, Skates SJ, et al:
Comparison of fibulin-3 and mesothelin as markers in malignant
mesothelioma. Thorax. 69:895–902. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
van Zandwijk N, Clarke C, Henderson D,
Musk AW, Fong K, Nowak A, Loneragan R, McCaughan B, Boyer M, Feigen
M, et al: Guidelines for the diagnosis and treatment of malignant
pleural mesothelioma. J Thorac Dis. 5:E254–E307. 2013.
|
|
33
|
Xu RH, Wei W, Krawczyk M, Wang W, Luo H,
Flagg K, Yi S, Shi W, Quan Q, Li K, et al: Circulating tumour DNA
methylation markers for diagnosis and prognosis of hepatocellular
carcinoma. Nat Mater. 16:1155–1161. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Pishvaian MJ, Joseph Bender R, Matrisian
LM, Rahib L, Hendifar A, Hoos WA, Mikhail S, Chung V, Picozzi V,
Heartwell C, et al: A pilot study evaluating concordance between
blood-based and patient-matched tumor molecular testing within
pancreatic cancer patients participating in the Know Your Tumor
(KYT) initiative. Oncotarget. 8:83446–83456. 2016.
|
|
35
|
Liggett T, Melnikov A, Yi QL, Replogle C,
Brand R, Kaul K, Talamonti M, Abrams RA and Levenson V:
Differential methylation of cell-free circulating DNA among
patients with pancreatic cancer versus chronic pancreatitis.
Cancer. 116:1674–1680. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Hoque MO, Feng Q, Toure P, Dem A,
Critchlow CW, Hawes SE, Wood T, Jeronimo C, Rosenbaum E, Stern J,
et al: Detection of aberrant methylation of four genes in plasma
DNA for the detection of breast cancer. J Clin Oncol. 24:4262–4269.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Worm Ørntoft MB: Review of blood-based
colorectal cancer screening: how far are circulating cell-free DNA
methylation markers from clinical implementation? Clin Colorectal
Cancer. 17:e415–e433. 2018. View Article : Google Scholar
|
|
38
|
Stewart CM, Kothari PD, Mouliere F, Mair
R, Somnay S, Benayed R, Zehir A, Weigelt B, Dawson SJ, Arcila ME,
et al: The value of cell-free DNA for molecular pathology. J
Pathol. 244:616–627. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Diehl F, Schmidt K, Choti MA, Romans K,
Goodman S, Li M, Thornton K, Agrawal N, Sokoll L, Szabo SA, et al:
Circulating mutant DNA to assess tumor dynamics. Nat Med.
14:985–990. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Bettegowda C, Sausen M, Leary RJ, Kinde I,
Wang Y, Agrawal N, Bartlett BR, Wang H, Luber B, Alani RM, et al:
Detection of circulating tumor DNA in early- and late-stage human
malignancies. Sci Transl Med. 6:224ra242014. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Thierry AR, Mouliere F, El Messaoudi S,
Mollevi C, Lopez-Crapez E, Rolet F, Gillet B, Gongora C, Dechelotte
P, Robert B, et al: Clinical validation of the detection of KRAS
and BRAF mutations from circulating tumor DNA. Nat Med. 20:430–435.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Zeng H, He B, Yi C and Peng J: Liquid
biopsies: DNA methylation analyses in circulating cell-free DNA. J
Genet Genomics. 45:185–192. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Jung M, Klotzek S, Lewandowski M,
Fleischhacker M and Jung K: Changes in concentration of DNA in
serum and plasma during storage of blood samples. Clin Chem.
49:1028–1029. 2003. View Article : Google Scholar : PubMed/NCBI
|
